Gregory M. Weinhoff Sells 11,742 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 11,742 shares of Centessa Pharmaceuticals stock in a transaction on Friday, October 25th. The shares were sold at an average price of $15.38, for a total value of $180,591.96. Following the sale, the insider now directly owns 183,266 shares of the company’s stock, valued at approximately $2,818,631.08. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Centessa Pharmaceuticals Price Performance

Shares of CNTA stock opened at $15.50 on Friday. Centessa Pharmaceuticals plc has a 1-year low of $5.58 and a 1-year high of $17.59. The stock’s fifty day moving average price is $15.04 and its 200 day moving average price is $11.51. The company has a debt-to-equity ratio of 0.27, a current ratio of 13.29 and a quick ratio of 13.29. The company has a market cap of $1.56 billion, a price-to-earnings ratio of -10.92 and a beta of 1.46.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Tuesday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). On average, research analysts expect that Centessa Pharmaceuticals plc will post -1.68 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CNTA has been the subject of a number of research analyst reports. B. Riley started coverage on Centessa Pharmaceuticals in a research report on Thursday, September 19th. They set a “buy” rating and a $33.00 target price for the company. Morgan Stanley raised Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $11.00 to $26.00 in a research report on Thursday, September 19th. Oppenheimer reissued an “outperform” rating and issued a $14.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. Jefferies Financial Group boosted their price target on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Finally, BMO Capital Markets boosted their price target on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research report on Monday, September 16th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $25.17.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. grew its stake in Centessa Pharmaceuticals by 47.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after purchasing an additional 826 shares during the last quarter. GAMMA Investing LLC grew its stake in Centessa Pharmaceuticals by 103.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after purchasing an additional 1,509 shares during the last quarter. Quarry LP grew its stake in Centessa Pharmaceuticals by 47.8% during the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock valued at $87,000 after purchasing an additional 3,108 shares during the last quarter. Sandia Investment Management LP purchased a new stake in Centessa Pharmaceuticals during the 2nd quarter valued at about $90,000. Finally, Fred Alger Management LLC purchased a new stake in Centessa Pharmaceuticals during the 2nd quarter valued at about $99,000. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.